GeoVax Labs, Inc. is a biotechnology company, established to develop,
manufacture, license and commercialize human vaccines for diseases caused
by HIV-1 (Human Immunodeficiency Virus) and other infectious agents.
GeoVax's vaccine technology is covered by 20 issued or filed patent
applications. GeoVax HIV/AIDS vaccines are designed to prevent development
of Acquired Immunodeficiency Disease (AIDS), caused by the virus known as
HIV-1, by vaccinating individuals prior to infection with the AIDS virus.
In addition, GeoVax AIDS vaccines may be effective as therapeutics
(treatment of people infected with AIDS virus). Studies evaluating these
vaccines in already HIV/AIDS infected individuals are being planned.
GeoVax DNA and Recombinant MVA HIV/AIDS vaccines:
-- Use DNA vaccines to "prime" immune responses and MVA vaccines to
"boost" immune responses against the AIDS virus
-- Express more than 50% of AIDS virus components in vaccinees and can
not cause AIDS
-- Protected 22 of 23 (96%) non-human primates against development of
AIDS for over 3 1/2 years
-- Are manufactured & tested under GMP/GLP - EMEA (EU) and FDA guidelines
-- Satisfactorily completed 2 earlier DNA & DNA/MVA -- HIV/AIDS vaccine
Phase 1 human trials
-- Are currently being tested in 3 Human Trials. One started in 2006, two
in summer 2007
-- Have been demonstrated safe to date in human trials
-- Are demonstrating positive immune responses against HIV in the
majority of vaccine recipients
-- Are in planning stage for larger Phase 2 human trial in 2008
About Financial Relations Board
For more than 40 years, the Financial Relations Board has been one of
the nation's leaders for investor relations and financial communications.
The firm offers a full array of services, including deep expertise in
corporate positioning and communication, investment
|SOURCE GeoVax Labs, Inc.|
Copyright©2007 PR Newswire.
All rights reserved